- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/04 - Antineoplastic agents specific for metastasis
Patent holdings for IPC class A61P 35/04
Total number of patents in this class: 4690
10-year publication summary
132
|
137
|
164
|
321
|
470
|
483
|
571
|
566
|
489
|
134
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Novartis AG | 11238 |
48 |
Genentech, Inc. | 3742 |
48 |
The Regents of the University of California | 18943 |
46 |
Board of Regents, The University of Texas System | 5370 |
36 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
34 |
Memorial Sloan-Kettering Cancer Center | 1789 |
32 |
Takeda Pharmaceutical Company Limited | 2961 |
30 |
Dana-Farber Cancer Institute, Inc. | 2455 |
29 |
Eisai R&D Management Co., Ltd. | 1304 |
28 |
AstraZeneca AB | 3042 |
27 |
F. Hoffmann-La Roche AG | 7958 |
25 |
Pfizer Inc. | 3322 |
23 |
Janssen Pharmaceutica N.V. | 3839 |
22 |
Taisho Pharmaceutical Co., Ltd. | 844 |
21 |
Bristol-myers Squibb Company | 5080 |
20 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
20 |
Daiichi Sankyo Company, Limited | 1829 |
20 |
Lunella Biotech, Inc. | 93 |
20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
19 |
The General Hospital Corporation | 4517 |
18 |
Other owners | 4124 |